Latest Technology Platform News

Steadfast Group delivered double-digit underlying EBITA growth in FY26 alongside a recommended $6 per share acquisition offer, reflecting a premium of nearly 52%. The insurer broker network continues to expand, supported by technology upgrades and international acquisitions.

Beforepay Group reported a 57% jump in cash NPAT to $15.7 million for FY26, driven by strong advances growth and scaling of its Personal Loans product. The company also secured a $100 million credit facility to fuel further expansion.

SiteMinder Limited (ASX:SDR) nearly doubled its adjusted EBITDA to $28.1 million in FY26, driven by a 22% revenue increase and strong adoption of its AI-powered Smart Platform. The company narrowed its net loss by more than half amid ongoing investments in growth and operational efficiency.

Bendigo and Adelaide Bank reports a $375.1 million statutory profit for FY26, reversing last year’s loss, while committing $70 million to a multi-year risk rectification program and declaring a fully franked 33 cent dividend.

Ovanti Limited has launched a 1-for-1 entitlement offer to raise approximately AUD 2.293 million at 0.2 cents per share, targeting working capital and offer costs. The offer closes on 1 September 2026 and includes a top-up facility for additional shares.

Environmental Clean Technologies has secured A$10.6 million in a placement to fast-track commercialisation of its Flash Joule Heating platform and MXene manufacturing, backed by a strategic acquisition and feedstock supply.

Viva Leisure posted a 12.2% revenue increase to $237.1 million and a 144.5% jump in net profit after tax for FY2026, declaring its first fully franked dividend and launching Meridium Global as a standalone payments and technology business.

EML Payments reported a 6% revenue decline and an 18% drop in underlying EBITDA for FY26, completing a major restructuring and advancing its Arlo technology platform. The company projects FY27 EBITDA between $50 million and $54 million, with a strong new program pipeline and strategic investments underpinning growth.

Cogstate Ltd (ASX:CGS) posted a 15.9% rise in profit before tax to US$16.1 million for FY26, driven by a 116% surge in clinical trial sales contracts to $89 million and a 15% revenue increase. The company doubled its final dividend to A$0.04 per share, supported by a strong $118.5 million contracted revenue backlog.

Challenger Limited delivered a solid FY26 with normalised net profit after tax rising 3% to $468 million, supported by record annuity sales and strategic partnerships. The company also declared a 7% higher fully franked dividend and announced an upsized $450 million share buy-back.

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

Fiducian Group posted solid underlying earnings growth in FY2026, boosted by a 7% rise in funds under management, advice and administration, while absorbing a one-off $7.95 million ASIC penalty that halved statutory profits.